Home
News
Create
Screeners
Insights
Indo Us Bio-Tech
100.
95
-0.72
(-0.71%)
Market Cap
₹202.42 Cr
PE Ratio
78.58
Industry
FMCG
Buy
Sell
Company Performance:
1D
-0.71%
1M
-5.56%
6M
-17.75%
1Y
-32.11%
5Y
-65.50%
View Company Insights
Latest news about Indo Us Bio-Tech
Indo Us Bio Tech board to meet on May 29 to consider Q4FY26 results
1 day ago
Yesterday
Indo Us Bio Tech Limited will hold a board meeting on May 29, 2026, to approve the audited financial results for the quarter and year ending March 31, 2026. The trading window is closed from April 1 to May 30, 2026.
Indo US Bio-Tech Appoints Mrs. Hemanshi Darsh Soni as Independent Director
Apr 23, 2026
Indo US Bio-Tech Limited Announces Resignation of Independent Director Mrs. Nehaben Sachinbhai Patel
Apr 23, 2026
Indo Us Bio-Tech Limited Submits SEBI Compliance Certificate for FY2026
Apr 06, 2026
Indo Us Bio-Tech Limited Issues Clarification on Recent Stock Price Movement
Mar 11, 2026
More news about Indo Us Bio-Tech
05
Mar 26
Indo-US Agriseeds Limited Reduces Stake in Indo US Bio-Tech Limited Through Open Market Sale
Indo-US Agriseeds Limited disclosed the sale of 50,000 shares in Indo US Bio-Tech Limited through open market transactions on March 2, 2026, reducing its shareholding from 9.0742% to 8.8249%. The transaction was reported under SEBI Takeover Regulations, with the company maintaining its promoter group status in the target company. Indo US Bio-Tech Limited has an equity share capital of 2,00,52,000 shares and is listed on BSE and NSE.
12
Feb 26
Indo-US Agriseeds continues stake reduction with 75,000 share sale
Indo-US Agriseeds Limited has disclosed another share sale in Indo US Bio-Tech Limited, selling 75,000 equity shares through open market operations on February 11, 2026. This latest transaction reduced the company's shareholding from 19,44,569 shares (9.6976%) to 18,69,569 shares (9.3236%) of the total voting capital.
21
Jan 26
Indo US Bio-Tech Reports Q3 FY26 Results with Net Profit of ₹299.66 Lakhs
Indo US Bio-Tech Limited reported Q3 FY26 net profit of ₹299.66 lakhs, down 40.7% from ₹505.45 lakhs in Q3 FY25, while revenue declined marginally to ₹2,279.83 lakhs. Nine-month performance showed revenue growth of 19.8% to ₹8,441.44 lakhs, though net profit decreased 11.4% to ₹1,115.11 lakhs. The auditors expressed qualified opinion due to incomplete assessment of new Labour Codes impact.
29
Dec 25
Indo US Bio-Tech Receives ED Summons Under PMLA for Inquiry Purposes
Indo US Bio-Tech Limited has received summons from the Directorate of Enforcement (ED) under the Prevention of Money Laundering Act (PMLA), 2002. The summons, dated November 20, 2025, requires the company's Principal Officer to appear and produce specific information and documents for investigation. The company stated that no formal charges have been made and no immediate material impact on financial or operational activities is expected. The disclosure was made to stock exchanges on December 29, 2025, with the company acknowledging a delay in reporting due to internal review processes.
Indo Us Bio-Tech
100.
95
-
0.
72
(-
0.
71
%)
1 Year Returns:
-32.11%
Industry Peers
LT Foods
396.45
(-
1.
45
%)
KRBL
343.80
(+
1.
78
%)
Gujarat Ambuja Exports
163.44
(-
1.
14
%)
Kaveri Seed Company
918.35
(+
0.
22
%)
Trualt Bioenergy
495.10
(+
3.
54
%)
GRM Overseas
162.33
(-
1.
10
%)
Sanstar
116.79
(-
1.
50
%)
Chaman Lal Setia Exports
266.70
(+
1.
12
%)
Gulshan Polyols
189.42
(-
7.
02
%)
Avt Natural Products
68.02
(+
2.
42
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar